Technical Review: Local Delivery of IL-12 mRNA and Indoximod Prodrug for Enhanced Cancer Immunotherapy
- aprilt97
- Jul 14
- 3 min read
Authors: Heewon Park, In Kang, Susam Lee, Minsa Park, Seungcheol Kim, Su Yeon Lim, Hoyeon Nam, Dohyun Yun, Sejin Kim, Yesol Kim, Ji Hoon Jeong, Kyuri Lee, Heung Kyu Lee, Yong-kyu Lee, Yeu-Chun Kim
Affiliation: Department of Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea
Background Introduction
This research falls within the rapidly evolving field of cancer immunotherapy and nanomedicine, specifically focusing on cytokine-based therapeutic approaches, specifically IL-12 cytokine therapy. IL-12 has demonstrated potent antitumor activity in preclinical models by promoting T helper type 1 (TH1) differentiation and enhancing cytotoxic T lymphocyte activity. However, systemic administration causes severe dose-limiting toxicities, while local delivery, though safer, faces the problem of transient efficacy. This is primarily due to IFNγ-dependent indoleamine 2,3-dioxygenase (IDO) pathway activation, which promotes T regulatory cell proliferation.
Materials and Methodology
The researchers employed a systematic approach to develop a co-delivery system combining IL-12 mRNA with an indoximod (IND) prodrug using lipid nanoparticles (LNPs).
The usage of LNPs seeks to overcome solubility limitations of free IND in organic solvents by providing IND with a robust carrier.
Three LNP formulations were systematically tested with varying ratios of IND replacing cholesterol components. For in vitro studies, both macrophages (RAW264.7) and tumor cell lines (B16F10 and MC38) were transfected and with reporter genes and IL-12 expression. Immune modulation was further studied by assessing macrophage polarization markers and T cell activation. Finally, for in vivo studies, a B16F10 subcutaneous xenograft model was used with mice, with LNPs regularly injected and tumor volumes closely monitored.
Results
LNP Optimization and Characterization
The study identified formulation LNP1 (50% cholesterol replacement with IND) as optimal, showing enhanced in vitro transfection efficiency while maintaining good in vivo performance. Interestingly, complete cholesterol replacement (LNP2) improved in vitro transfection but significantly reduced in vivo efficacy, likely due to compromised LNP stability.
IL-12 Expression and Immune Modulation
The optimized IDO-inhibiting LNPs (IDOi LNPs) successfully transfected both tumor cells and macrophages, achieving over 80% IL-12 p40-positive cells in B16F10 cultures. Transfected macrophages showed significant upregulation of M1 markers (CD80, CD86, CD40) and increased TNFα secretion, indicating successful reprogramming from immunosuppressive M2 to pro-inflammatory M1 phenotype.
In Vivo Therapeutic Efficacy
The therapeutic studies demonstrated compelling antitumor activity. While LNPs containing only IL-12 mRNA were unable to sustain T cell activation despite initial transfection, the IDOi LNP group showed enhanced efficacy with a more than two-fold increase in survival rates. Importantly, the synergistic effect became more apparent with extended dosing intervals (7-day vs. 3-day intervals), suggesting sustained immune activation through IDO pathway inhibition.
Immune Cell Profiling
Flow cytometry analysis revealed detailed immune modulation mechanisms. On day 2 post-treatment, both LNP and IDOi LNP groups showed increased M1 macrophages (CD80+CD86+) and decreased M2 macrophages (CD206+Arginase1+). By day 7, the IDOi LNP group demonstrated superior CD8+ T cell infiltration and enhanced polyfunctionality, with increased IFNγ and TNFα production capacity. Notably, the IDOi LNP group also showed reduced T regulatory cell populations, particularly the CD25-Foxp3+ subset.
Conclusion
Park and colleagues demonstrated the strength of mRNA-LNPs for cancer immunotherapy.
The optimized LNPs addressed several challenges of IND delivery, while a combination of IL-12 mRNA and IDO pathway inhibition greatly improved survivability. This opens new avenues for cytokine immunotherapy approaches. For example, future research could investigate synergistic effects with other small molecule inhibitors or immunosuppressive pathways.
The PreciGenome NanoGenerator Flex-M was critical for the performance requirements of this project. Controlled microfluidic mixing ensured high product consistency and repeatability, while its versatile production range was ideal for preclinical studies on small animal models.
For further details, check out the link to the article here:
Comments